Elite Pharmaceuticals Inc (ELTP)

[RizZo]

Elite Pharmaceuticals Announces Commercial Launch of Generic Adderall XR(R) with Marketing Partner Lannett Company


NORTHVALE, NJ / ACCESSWIRE / March 31, 2020 / Elite Pharmaceuticals, Inc.
("Elite" or the "Company") (OTCQB:ELTP) a specialty pharmaceutical company
developing niche generic products, announced today that marketing partner
Lannett Company, Inc. ("Lannett"), has commenced product launch of Elite's
generic version of Adderall XR®, an extended-release mixed salt of a single
entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine
Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5
mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules. Adderall XR®, including
generic versions, have an estimated IQVIA™ market value of approximately $1.3
billion for the twelve months ending January 2020. Adderall XR® is a
once-daily central nervous system stimulant and is indicated for the treatment
of Attention Deficit Hyperactivity Disorder (ADHD).

This generic Adderall XR® product is jointly owned by Elite and SunGen Pharma
LLC ("SunGen") and is the second product launched from their collaboration.
Elite will manufacture and package the generic product on a cost-plus basis.
Lannett Company, Inc. will be the exclusive U.S. distributor for the product
and will provide sales, marketing, and distribution.


https://www.bloomberg.com/press-releases/2020-03-31/elite-pharmaceuticals-announces-commercial-launch-of-generic-adderall-xr-r-with-marketing-partner-lannett-company